Mapracorat

Phase 3Small molecule

Bayer

Mapracorat is one of 79 small molecule programs targeting Allergic Conjunctivitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic ConjunctivitisActive, not recruiting

CataractActive, not recruiting

Atopic DermatitisActive, not recruiting

Allergic ConjunctivitisPhase 2

Active, not recruiting

CataractPhase 3

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Tagamet

DDT MedTech, LLC

Phase 3

1 2

Calcineurin Inhibitors

Sanofi

Phase 3

1 3

GR1802

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase 3

1 4

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

6 5

Verdeso

PPadagis LLC

Phase 3

1 6

Mapracorat

Bayer

Phase 3

1 7

EBGLYSS

Eli Lilly

Preclinical

23 8

Cibinqo

Pfizer

Preclinical

11 9

Prograf

VVeloxis Pharmaceuticals

Preclinical

18 10

Eucrisa

WWake Forest University Health Sciences

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cataract4 trials

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed·BBausch & Lomb Incorporated·Phase 3·NCT01591161·369 enrolled

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed·BBausch & Lomb Incorporated·Phase 3·NCT01591655·360 enrolled

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Completed·BBausch & Lomb Incorporated·Phase 3·NCT01230125·311 enrolled

Show 1 more trial

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Terminated·BBausch & Lomb Incorporated·Phase 3·NCT01298752·177 enrolled

Adult2 trials

HPA Axis Study in Adults

Completed· Bayer logo

Bayer·Phase 2·NCT01408511·23 enrolled

HPA Axis Study in Japanese Adults

Completed· Bayer logo

Bayer·Phase 2·NCT01407510·12 enrolled

Atopic Dermatitis1 trial

Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)

Completed· Bayer logo

Bayer·Phase 2·NCT01359787·197 enrolled

Allergic Conjunctivitis1 trial

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Completed·BBausch & Lomb Incorporated·Phase 2·NCT01289431·236 enrolled

Plaque1 trial

1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat

Completed· Bayer logo

Bayer·Phase 1·NCT03399526·24 enrolled

1 more indication

Unspecified1 trial

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

Completed·BBausch & Lomb Incorporated·Phase 1·NCT01736462·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Mapracorat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mapracorat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mapracorat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Mapracorat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cataract4 trials

Adult2 trials

Atopic Dermatitis1 trial

Allergic Conjunctivitis1 trial

Plaque1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News